ArticleFrontiers in immunology2025
Development and validation of a novel sodium-overload related genes signature for prognostic prediction in breast cancer: integrating bioinformatics and experimental approaches.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sodium Overload-Related Molecular Subtypes and a Four-Gene Prognostic Signature Predict Survival, Immune Landscape, and Therapeutic Response in Acute Myeloid Leukemia.Molecular carcinogenesis · 2026Article
- Necrosis by Sodium Overload: Mechanisms, Pathophysiological Roles, and Therapeutic Prospects of a Novel Form of Regulated Cell Death.Cell biochemistry and biophysics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Necrosis induced by sodium overload has recently been identified as a novel form of regulated cell death. However, the specific genes associated with sodium overload in breast cancer (BC) remain uncharacterized. Methods: We identified 753 differentially expressed sodium-overload-related genes (DESORGs) in BC. We performed pathway enrichment analyses, then used univariate Cox regression to select 67 prognostic DESORGs. To build prognostic models, we tested 101 combinations of ten machine learning algorithms. SHAP analysis was used to determine feature importance. Mendelian randomization (MR) was applied to assess causal effects. Experimental validation (in vitro) included overexpression and knockdown studies. GSEA/GSVA and molecular docking were conducted to explore downstream pathways and potential drug candidates. Results: The ridge regression model showed optimal prognostic power. IFNG was identified as the key feature. The computed risk score was an independent prognostic factor, outperforming traditional clinical variables (AUC = 0.845), and a nomogram built with it yielded good calibration (C-index = 0.815). MR suggested a protective causal effect of NR1H3 in BC, and patients with high NR1H3 expression had significantly better overall survival (p = 0.02). Conclusions: These findings highlight NR1H3 as a novel DESORG and a promising therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.